[The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)]

Multiple myeloma (MM) is a clonal plasma cell disorder, the second most hematological malignancy. MM mainly develops in elderly people and remains incurable at present. With the development of novel agents and advances of laboratory evaluation, the diagnosis and treatment of MM have been significantly improved. In this version, an anti-CD38 monoclonal antibody, Daratumumab, based regimens and related concerns were appended. The chimeric antigen receptor T cell (CAR-T) immunotherapy was updated in the section of relapse and refractory myeloma. Again, autologous stem cell transplantation (ASCT) is still the standard consolidation after front-line therapy for transplant candidates with MM.